Pulmonary Arterial Hypertension pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

July 2020 | 290 pages | ID: PDD70B60FD3FEN
VPAResearch

Abstracts

2020 Pulmonary Arterial Hypertension PIPELINE HIGHLIGHTS
Pulmonary Arterial Hypertension is one of the widely researched conditions during 2020 with 72 companies actively focusing on realizing pipeline’s potential. Development of Pulmonary Arterial Hypertension medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Pulmonary Arterial Hypertension market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Pulmonary Arterial Hypertension.

Good progress is anticipated during 2020 and 2021 with Pulmonary Arterial Hypertension pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Pulmonary Arterial Hypertension pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Pulmonary Arterial Hypertension DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Pulmonary Arterial Hypertension pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Pulmonary Arterial Hypertension pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Pulmonary Arterial Hypertension presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Pulmonary Arterial Hypertension pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Pulmonary Arterial Hypertension DRUG PROFILES
Pulmonary Arterial Hypertension development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-

• Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
• Phase of development
• Mechanism of Action
• Route of Administration
• Companies involved including originator, licensing companies, developer, investors, and others
• New molecular entity details
• Orphan drug designation and other special status provided by regulators

Pulmonary Arterial Hypertension COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Pulmonary Arterial Hypertension drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Pulmonary Arterial Hypertension. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 72 Pulmonary Arterial Hypertension companies including company overview, key snapshot, contact information, and their strategies on accelerating Pulmonary Arterial Hypertension pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Aadi Bioscience Inc, Abivax SA, Acceleron Pharma Inc, Actelion Pharmaceuticals, Aerogen Pharma Limited, AI Therapeutics, Altavant Sciences Inc, Apaxen, Apollo Therapeutics LLC, APT Therapeutics, Inc., Aqualung Therapeutics Corp, ATXA Therapeutics Ltd, AVEO Pharmaceuticals Inc., Bayer AG, Bial – Portela & Ca SA, Biogen Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co, C4X Discovery Holdings Plc, Camurus AB, Capricor Therapeutics Inc, Celsion Corp, Celtaxsys Inc, Cereno Scientific AB, Chiesi Farmaceutici SpA, Chugai Pharmaceutical Co Ltd, Complexa Inc, Corsair Pharma Inc, Denovo Biopharma LLC, Eli Lilly and Co, Galectin Therapeutics Inc, GenThera Inc, GEXVal Inc, Gilead Sciences Inc, Gmax Biopharm Biomedical Engineering Co., Ltd., Gossamer Bio Inc, Hanmi Pharmaceuticals Co Ltd, Insmed Inc, Invent Pharmaceuticals, Inc. , Karos Pharmaceuticals, Inc, Liquidia Technologies Inc, LTT Bio-Pharma Co., Ltd., Martin Pharmaceuticals Inc, Merck & Co Inc, Mezzion Pharma Co Ltd, Mifcare.ca, MORPHOGEN-IX Limited, Nippon Shinyaku Co Ltd, Northern Therapeutics Inc, Novartis International AG, Pfizer Inc, Pharmosa Biopharm Inc, PhaseBio Pharmaceuticals, Inc, Proteo Biotech AG, Pulmokine, Inc, Radikal Therapeutics Inc, Reata Pharmaceuticals Inc, Relief Therapeutics Holding AG, Respira Therapeutics, Inc, Resverlogix Corp, Reviva Pharmaceuticals, Inc, Sosei Heptares, SteadyMed Therapeutics Inc, Suda Ltd, Sulfateq BV, Topadur Pharma AG, Translate Bio Inc, Tritech Biopharmaceuticals Co Ltd, United Therapeutics Corp, Vascular BioSciences, Vasculonics LLC, Vivus Inc

REASONS TO BUY

• The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
• This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
• Buyers can identify most promising drug candidates for treatment of Pulmonary Arterial Hypertension
• It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
• Users can estimate possible delays in the delivery of pipeline or launch of new products
• Stay ahead of competition through understanding their pipeline progression, strategies and outlook
• The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
• Optimize your licensing and technology transfer strategies through identification of prospect partners

Contents

1. INTRODUCTION TO PULMONARY ARTERIAL HYPERTENSION

1.1 Pulmonary Arterial Hypertension- Disease overview
1.2 Pulmonary Arterial Hypertension- Market Size
1.3 Pulmonary Arterial Hypertension- Companies Involved

2. PULMONARY ARTERIAL HYPERTENSION PIPELINE SNAPSHOT- 2020

2.1 Pulmonary Arterial Hypertension Pipeline by Phase
2.2 Pulmonary Arterial Hypertension Pipeline by Mechanism of Action
2.3 Pulmonary Arterial Hypertension Pipeline by Route of Administration
2.4 Pulmonary Arterial Hypertension Pipeline- New Molecular Entities
2.5 Pulmonary Arterial Hypertension Pipeline- Orphan Drug Designation/ Special Designation

3. PULMONARY ARTERIAL HYPERTENSION DRUG PROFILES

3.1 Current Status
3.2 Pulmonary Arterial Hypertension Drug Snapshot
3.3 Pulmonary Arterial Hypertension Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Aadi Bioscience Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.2 Abivax SA Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.3 Acceleron Pharma Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.5 Aerogen Pharma Limited Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.6 AI Therapeutics Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.7 Altavant Sciences Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.8 Apaxen Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.9 Apollo Therapeutics LLC Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.10 APT Therapeutics, Inc. Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.11 Aqualung Therapeutics Corp Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.12 ATXA Therapeutics Ltd Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.13 AVEO Pharmaceuticals Inc. Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.14 Bayer AG Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.15 Bial – Portela & Ca SA Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.16 Biogen Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.17 Boehringer Ingelheim International GmbH Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.18 Bristol-Myers Squibb Co Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.19 C4X Discovery Holdings Plc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.20 Camurus AB Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.21 Capricor Therapeutics Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.22 Celsion Corp Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.23 Celtaxsys Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.24 Cereno Scientific AB Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.25 Chiesi Farmaceutici SpA Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.26 Chugai Pharmaceutical Co Ltd Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.27 Complexa Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.28 Corsair Pharma Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.29 Denovo Biopharma LLC Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.30 Eli Lilly and Co Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.31 Galectin Therapeutics Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.32 GenThera Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.33 GEXVal Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.34 Gilead Sciences Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.35 Gmax Biopharm Biomedical Engineering Co., Ltd. Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.36 Gossamer Bio Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.37 Hanmi Pharmaceuticals Co Ltd Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.38 Insmed Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.39 Invent Pharmaceuticals, Inc. Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.40 Karos Pharmaceuticals, Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.41 Liquidia Technologies Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.42 LTT Bio-Pharma Co., Ltd. Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.43 Martin Pharmaceuticals Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.44 Merck & Co Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.45 Mezzion Pharma Co Ltd Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.46 Mifcare.ca Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.47 MORPHOGEN-IX Limited Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.48 Nippon Shinyaku Co Ltd Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.49 Northern Therapeutics Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.50 Novartis International AG Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.51 Pfizer Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.52 Pharmosa Biopharm Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.53 PhaseBio Pharmaceuticals, Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.54 Proteo Biotech AG Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.55 Pulmokine, Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.56 Radikal Therapeutics Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.57 Reata Pharmaceuticals Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.58 Relief Therapeutics Holding AG Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.59 Respira Therapeutics, Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.60 Resverlogix Corp Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.61 Reviva Pharmaceuticals, Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.62 Sosei Heptares Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.63 SteadyMed Therapeutics Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.64 Suda Ltd Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.65 Sulfateq BV Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.66 Topadur Pharma AG Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.67 Translate Bio Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.68 Tritech Biopharmaceuticals Co Ltd Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.69 United Therapeutics Corp Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.70 Vascular BioSciences Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.71 Vasculonics LLC Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials
4.72 Vivus Inc Pulmonary Arterial Hypertension Pipeline Insights and Clinical Trials

5. PULMONARY ARTERIAL HYPERTENSION MARKET NEWS AND UPDATES

6. APPENDIX

6.1 Sources and Methodology
6.2 Contact Information